Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAT-Lipo-Dox
- Development stage
- Preclinical
- Lead developer
- Northeastern University
- Modality
- Small Molecules, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TAT-Lipo-Dox is a preclinical, cell-penetrating peptide-modified liposomal formulation of the anthracycline chemotherapeutic agent doxorubicin. It consists of doxorubicin encapsulated within liposomes that are surface-decorated with the transactivator of transcription (TAT) peptide, a cationic cell-penetrating peptide derived from HIV-1. The TAT peptide enhances the cellular internalization and nuclear localization of the liposomal nanoparticles, thereby increasing intracellular drug delivery and cytotoxicity against cancer cells. This formulation is designed to overcome multidrug resistance (MDR) and improve the therapeutic index of doxorubicin by enhancing its accumulation in tumor tissues while potentially reducing systemic toxicities, such as cardiotoxicity, associated with free doxorubicin.
- Other names
- TAT-Lipo-DOXTAT-liposomal DOXTAT-liposomal doxorubicinTAT-modified liposomal DOXTAT-modified liposomal doxorubicin
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on TAT-Lipo-Dox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAT-Lipo-Dox.